Method for establishing anti-hepatitis C virus drug screening experimental animal model

A hepatitis C virus and drug technology, applied in the field of establishing anti-hepatitis C virus drug screening, can solve the problems of low model success rate, simple genotype, and low virus concentration, and achieve the effect of high model success rate

Inactive Publication Date: 2006-12-20
李卫云
View PDF0 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, since the virus used for research comes from the patient's serum, the virus concentration is not high, and there is no effective and feasible method and technology for

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method for establishing anti-hepatitis C virus drug screening experimental animal model
  • Method for establishing anti-hepatitis C virus drug screening experimental animal model
  • Method for establishing anti-hepatitis C virus drug screening experimental animal model

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0032] Embodiment 1, artificial synthesis and quantification of hepatitis C virus

[0033] ①Synthesis of hepatitis C virus

[0034] Take the carrier pHCV-2 (CCTCC M201013) obtained in patent 200311111111, take 1 μg of ScaI enzyme-digested pHCV-2 and add it to 100 μl of OPTI-MEM, take 1 μg of pHCV-2 and add it to 100 μl of OPTI-MEM and let it stand at room temperature for 15 minutes; And take 5 microliters of LF2000 and add 95 microliters of OPTI-MEM to mix at room temperature for 15 minutes, mix the carrier and LF2000, and transfect for 10 5 Hela cells, and two control groups without carrier and without LF2000, after 6 hours of transfection, remove the transfection medium and replace it with DMEM containing 2.5% fetal bovine serum, DMEM medium contains 10 7 pfu vTF7-3 (ATCC N0 VR-2153) recombinant poxvirus, and added rifampicin 10 mg / ml. After 2 hours of inoculation, the inoculum was removed and the cells were cultured in DMEM containing 2.5% fetal bovine serum. After 48-72...

Embodiment 2

[0041] Embodiment 2, establishment and confirmation of animal model:

[0042] Animal blood is drawn, and the hepatitis C virus in the animal is detected by PCR method, and the hepatitis C of the animal is screened. All experimental animals were negative in PCR test before being inoculated with artificially synthesized hepatitis C virus. The artificially synthesized virus was inoculated with 0.8ml from the tail vein, and 0.6ml was injected intraperitoneally on the second day and the third day respectively, the inoculation volume was 2ml, and the viral load of each animal was 10 5 C and above, divided into 7 groups. The success rate of the positive model after vaccination varies with the viral load, and the viral load of each animal is inoculated at 104c including 10 4 c, The success rate of establishing the animal model of hepatitis C virus is below 34%. Each animal was inoculated with a viral load of 10 9 c includes 10 9 c. The success rate of establishing the animal mode...

Embodiment 3

[0072] Example 3, Hepatitis C virus positive tree shrew model screening anti-hepatitis C virus drug selection.

[0073] Select 40 successfully infected animals (RT-PCR, positive immunohistochemistry) and randomly divide them into two groups, A and B, and draw blood from 10 animals in each group to detect HCV viral load with placebo (normal saline), PEG IFN-α- 2a (Roche), PEG IFN-α-2bRoche), ribavirin ribavirin, RBV Roche) administration, dose according to PEG IFN-α-2a 1.5μg / kgSQ (subcutaneous injection) once a week PEG IFN-α-2bRoche ) 1.0μg / kg SQ (subcutaneous injection) RBV once a week, body weight less than 150g 2mg orally twice a day, body weight greater than 150g 3mg orally twice a day after oral administration, draw blood at 1, 2, 4, and 8 weeks for HCV viral load quantity.

[0074] 1 week

[0075] 1 week

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a method for selecting anti-hepatitis C medicine, which injects the artifical hepatitis C virus into tree mouse with negative hepatitis C, to build the hepatitis C natural infection model; via following steps as (1) composing hepatitis C virus; (2) injecting it into normal tree mouse, while the virus carried amount of each animal is higher than 105c; (3) fixing the hepatitis C virus naturally to infect the tree mouse model; (40 using the mouse model with positive hepatitis C virus to select the anti- hepatitis C medicine.

Description

technical field [0001] The present invention relates to the field of hepatitis C virus. Specifically, the invention relates to a method for establishing anti-hepatitis C virus drug screening and an experimental animal model. Background technique [0002] About 170 million people worldwide are infected with hepatitis C virus (HCV) (Alter M, 1997). The infection rate in developed countries is nearly 2%, and the HCV natural infection rate in my country is about 2-3%, which belongs to the high infection area of ​​HCV (Wen Yumei, 1999). 70-80 of acute hepatitis C patients will develop into chronic hepatitis, and 5-10 of them will develop into liver cirrhosis and liver cancer (Jin Qi, 2001). Since Choo et al. successfully cloned and isolated HCV in 1989, the molecular biology research of HCV has made great progress. So far known HCV has 6 genotypes and more than 30 subtypes. However, because the cell receptor of HCV has not been fully determined, lack of efficient cell culture...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K49/00
Inventor 李卫云陈震球李汝润曲三莆陈韵陶剑
Owner 李卫云
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap